Daxor Corporation

NasdaqCM:DXR Stock Report

Market Cap: US$41.1m

Daxor Management

Management criteria checks 3/4

Daxor's CEO is Michael Feldschuh, appointed in Sep 2016, has a tenure of 8.33 years. directly owns 4.29% of the company’s shares, worth $1.76M. The average tenure of the management team and the board of directors is 6.2 years and 6.3 years respectively.

Key information

Michael Feldschuh

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.3yrs
CEO ownership4.3%
Management average tenure6.2yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Daxor reports Q2 results

Aug 25

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Jul 21

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

Mar 08
Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

Feb 27
A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

CEO Compensation Analysis

How has Michael Feldschuh's remuneration changed compared to Daxor's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

US$2m

Mar 31 2024n/an/a

US$984k

Dec 31 2023n/an/a

US$281k

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

US$4m

Mar 31 2023n/an/a

US$5m

Dec 31 2022US$100kUS$100k

US$5m

Sep 30 2022n/an/a

US$5m

Jun 30 2022n/an/a

US$4m

Mar 31 2022n/an/a

US$5m

Dec 31 2021US$100kUS$100k

US$5m

Sep 30 2021n/an/a

US$3m

Jun 30 2021n/an/a

US$294k

Mar 31 2021n/an/a

-US$706k

Dec 31 2020US$100kUS$100k

-US$2m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$100kUS$100k

-US$496k

Sep 30 2019n/an/a

-US$149k

Jun 30 2019n/an/a

US$197k

Mar 31 2019n/an/a

-US$344k

Dec 31 2018US$100kUS$100k

-US$886k

Compensation vs Market: Insufficient data to establish whether Michael's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Feldschuh (55 yo)

8.3yrs

Tenure

US$100,000

Compensation

Mr. Michael Richard Feldschuh has been the Chief Executive Officer and President of Daxor Corp. since September 21, 2016. Mr. Feldschuh served as Acting Chief Executive Officer and President of Daxor Corp....

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Feldschuh
Chief Scientific Officer & Directorno dataUS$127.92k0.74%
$ 305.2k
Michael Feldschuh
Chairman8.3yrsUS$100.00k4.29%
$ 1.8m
Robert Michel
CFO, Chief Compliance Officer & Corporate Secretary6.3yrsno data0.23%
$ 96.1k
Linda Cooper
Vice President of Development & Operations2yrsno datano data
Kathryn Kornafel
Senior VP of Marketing & Commercial Development6.6yrsno datano data
Guido Manzo
Vice President of Sales6yrsno datano data
Jean Oertel
Senior Vice President Commercialization & Customer Experienceno datano datano data
John Jefferies
Chief Medical Officerless than a yearno datano data

6.2yrs

Average Tenure

59yo

Average Age

Experienced Management: DXR's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Feldschuh
Chief Scientific Officer & Director7.9yrsUS$127.92k0.74%
$ 305.2k
Michael Feldschuh
Chairman12yrsUS$100.00k4.29%
$ 1.8m
Phillip Frost
Chairman of Medical Advisory Boardno datano datano data
Caleb DesRosiers
Independent Director3yrsUS$1.75k0.065%
$ 26.8k
Fred Gilbert
Member of Medical Advisory Boardno datano datano data
James Brassel
Member of Medical Advisory Boardno datano datano data
Edward Feuer
Independent Director9yrsUS$2.13k0.021%
$ 8.5k
Henry Cremisi
Independent Director4.6yrsUS$1.13k0%
$ 0
Joy Goudie
Independent Director4.6yrsUS$2.13k0.0062%
$ 2.6k

6.3yrs

Average Tenure

66yo

Average Age

Experienced Board: DXR's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 15:04
End of Day Share Price 2025/01/21 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Daxor Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Anthony VendettiMaxim Group
Scott HenryRoth Capital Partners